The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: Prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group

Journal of Bone and Mineral Metabolism

Volumn 24, Issue 3, 2006, Pages 219-225

  Shiraki, Masataka ^a   Kuroda, Tatsuhiko ^b   Nakamura, Toshitaka ^c   Fukunaga, Masao ^d   Hosoi, Takayuki ^e   Orimo, Hajime ^f   Makino, Kuniyoshi ^g  

^a RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^b Nishiyama Kogyo Ochanomizu Building 5F   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e Tokyo Metropolitan Institute of Gerontology   (Japan)

^f National Hospital Organization Kyoto Medical Center   (Japan)

^g TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

DPD; Fracture intervention study osteoporosis; Vertebral fracture

Indexed keywords

DEOXYPYRIDINOLINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INFORMATION PROCESSING; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POISSON DISTRIBUTION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; URINARY EXCRETION; VERTEBRA FRACTURE;

AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; FEMALE; FRACTURES, BONE; HUMANS; JAPAN; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; SAMPLE SIZE; SPINAL FRACTURES;

EID: 33645862885     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-005-0675-7     Document Type: Article

References (33)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795
2. SL Silverman ME Minshall W Shen KD Harper S Xie Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study 2001 The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from Multiple Outcomes of Raloxifene Evaluation Study Arthritis Rheum 44 2611 2619
3. A Oleksik P Lips A Dawson ME Minshall W Shen C Cooper J Kanis 2000 Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures J Bone Miner Res 15 1384 1392
4. JA Kanis EV [tmp] McCloskey 1992 Epidemiology of vertebral osteoporosis Bone 13 Suppl 2 S1 10
5. JR Center TV Nguyen D Schneider PN Sambrook JA Eisman 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878 882
6. DM Kado WS Browner L Palermo MC Nevitt HK Genant SR Cummings 1999 Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group Arch Intern Med 159 1215 1220
7. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541
8. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082
9. ST Harris NB Watts HK Genant CD [tmp] McKeever T Hangartner M Keller CH Chesnut 3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
10. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporosis Int 11 83 91
11. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gloer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645
12. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh EM Lemmel S Pors-Nielsen R Rizzoli HK Genant JY Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468
13. K Kushida M Shiraki T Nakamura H Kishimoto H Morii K Yamamoto K Kaneda M Fukunaga T Inoue M Nakashima H Orimo on behalf of the Alendronate/Alfacalcidol Fracture Intervention Study Group 2002 The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial Curr Ther Res Clin Exp 63 606 620
14. Director, Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare (1998) Guidelines Concerning Methods for Clinical Evaluation of Osteoporosis Drugs (Second Draft). Notification No 1010 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, dated November 2, 1998 (in Japanese). Japanese Minister of Health and Welfare, Tokyo
15. ES Siris PD Miller E Barrett-Connor KG Faulkner LE Wehren TA Abbott ML Berger AC Santora LM Sherwood 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment JAMA 286 2815 2822
16. E Barrett-Connor ES Siris LE Wehren PD Miller TA Abbott ML Berger AC Santora LM Sherwood 2005 Osteoporosis and fracture risk in women of different ethnic groups J Bone Miner Res 20 185 194
17. HD Nelson M Helfand SH Woolf JD Allan 2002 Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 137 529 541
18. S Fujiwara F Kasagi N Masunari K Naito G Suzuki M Fukunaga 2003 Fracture prediction from bone mineral density in Japanese men and women J Bone Miner Res 18 1547 1553
19. H Orimo Y Hayashi M Fukunaga T Sone S Fujiwara M Shiraki K Kushida S Miyamoto S Soen J Nishimura Y Oh-hashi T Hosoi I Gorai H Tanaka T Igai H Kishimoto Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research 2001 Diagnostic criteria for primary osteoporosis: year 2000 revision J Bone miner Metab 19 331 337
20. M Shiraki Y Shiraki C Aoki T Hosoi S Inoue M Kaneki Y Ouchi 1997 Association of bone Mineral density with apolipoprotein E phenotype J Bone Miner Res 12 1438 1445
21. HK Genant M Jergas L Palermo M Nevitt RS Valentin D Black SR Cummings 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group J Bone Miner Res 11 984 996
22. M Fukunaga T Nakamura M Shiraki T Kuroda H Ohta T Hosoi H Orimo 2004 Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women J Bone Miner Metab 22 104 110
23. DA Shoenfeld 1983 Sample-size formula for the proportional-hazards regression model Biometrika 39 499 503
24. MR [tmp] McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women. HIP Intervention Program Study Group N Engl J Med 344 333 340
25. CM Klotzbuecher PD Ross PB Landsman TA Abbott 3rd M Berger 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis J Bone Miner Res 15 721 739
26. PD Ross HK Genant JW Davis PD Miller RD Wasnich 1993 Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women Osteoporos Int 3 120 126
27. P Lips 1997 Epidemiology and predictors of fractures associated with osteoporosis Am J Med 103 3S 11S
28. DK Roy TW O'Neill JD Finn M Lunt AJ Silman 2003 Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS) Osteoporos Int 14 19 26
29. P Garnero E Hausherr MC Chapuy C Marcelli H Grandjean C Muller C Cormier G Breart PJ Meunier PD Delmas 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study J Bone Miner Res 11 1531 1538
30. PL van Daele MJ Seibel H Burger A Hofman DE Grobbee JP Van Leeuwen JC Brikenhager HA Pols 1996 Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study BMJ 312 482 483
31. HW Woitge MJ Seibel 2000 Risk assessment for osteoporosis. II. Biochemical markers of bone turnover: bone resorption indices Clin Lab Med 20 503 525 vi
32. P Garnero E Sornay-Rendu B Claustrat PD Delmas 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15 1526 1536
33. PD Delmas L van de Langerijt NB Watts R Eastell H Genant A Grauer DL Cahall IMPACT Study Group 2005 Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study J Bone Miner Res 20 557 563 (Epub 2004 Dec 6)